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Abstract Pro-inflammatory cytokines are released in septic
shock and impair cardiac function via the Jak-STAT path-
way. It is well known that sympathetic and thus cate-
cholamine signaling is activated thereafter to compensate for
cardiac dysfunction. The mechanism of such compensation
by catecholamine signaling has been traditionally under-
stood to be cyclic AMP-dependent protein kinase (PKA)-
mediated enforcement of cardiac contractility. We hypoth-
esized that the exchange protein activated by cAMP (Epac), a
newly identified target of cAMP signaling that functions
independently of PKA, also plays a key role in this mecha-
nism. In cultured cardiac myocytes, activation of Epac
attenuated the inhibitory effect of interleukin-6 on the
increase of intracellular Ca2? concentration and contractility
in response to isoproterenol, most likely through inhibition
of the Jak-STAT pathway via SOCS3, with subsequent
changes in inducible nitric oxide synthase expression. These
findings suggest a new role of catecholamine signaling in
compensating for cardiac dysfunction in heart failure. Epac
and its downstream pathway may be a novel target for
treating cardiac dysfunction in endotoxemia.
Keywords Epac  cAMP  Catecholamine  Contractility 
Cytokine  Jak-STAT
Introduction
The classic cyclic AMP (cAMP)/protein kinase (PKA)
pathway is a major regulator of cardiac function. Nore-
pinephrine released from the synaptic terminals binds to b-
adrenergic receptors, leading to activation of adenylyl
cyclase and thus the production of cAMP [1, 2]. cAMP, a
major second messenger, activates PKA, initiating cas-
cades of phosphorylation reactions of molecules involved
in myocyte contraction [3]. The final outcome of nore-
pinephrine/cAMP signaling is to increase cardiac contrac-
tility. It is well known that sympathetic nerve activity, and
thus cAMP production, is increased in response to
decreased cardiac function in heart failure.
For many decades, it was believed that the major target
of cAMP signaling is PKA and that the PKA-mediated
increase in myocyte contractility is the only mechanism
compensating for cardiac dysfunction in heart failure.
Recently, however, exchange protein activated by cAMP
(Epac) was identified as a new target of cAMP signaling
that is activated independently of PKA [4, 5]. Epac has two
isoforms (Epac1 and Epac2), and Epac1 is expressed
dominantly in the heart [4]. Although the exact role of
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these molecules in regulating cardiac function is not fully
understood, Epac has been shown to regulate various cel-
lular functions, such as migration, proliferation, skeletal
and masseter muscle hypertrophy, cardiac function, exo-
cytosis or cell apoptosis, via regulation of Rap1, a small
GTPase [4–11]. In cardiac myocytes, pharmacological
activation of Epac induces myocyte hypertrophy [12, 13].
Increased production of cytokines, especially inflam-
matory cytokines such as tumor necrosis factor alpha
(TNFa), interleukin-1 (IL-1) or IL-6, is responsible, at least
in part, for cardiac dysfunction in patients with heart failure
[14]. These inflammatory cytokines also play a role in
septic shock, which is induced by exposure to bacterial
endotoxin, leading to overproduction of these cytokines
[15]. Cytokine-induced inducible nitric oxide synthase
(iNOS) activation has been reported to play an important
role in the development of septic cardiomyopathy [16, 17].
Septic cardiomyopathy is a well-described complication of
severe sepsis, with more than two-thirds of patients
exhibiting cardiac dysfunction after the onset of septic
shock, even with a concomitant increase in sympathetic
nerve activity [18, 19]. Interestingly, it is also known that
the recovery of cardiac function is rapid and near-complete
in septic shock, despite the severity of cardiac dysfunction,
implying that activation of cAMP/Epac signaling may not
merely increase cardiac contractility.
Activation of cytokine receptors is linked to the janus
kinase–signal transducer and activator of transcription
(Jak-STAT) pathway, which is a major intracellular
signaling pathway [20]. Suppressor of cytokine signal-
ing-3 (SOCS3) protein is induced upon cytokine
receptor activation through STAT-dependent elements
in the promoter. SOCS3 exerts negative feedback effects
on cytokine signaling via the Jak-STAT pathway [21].
To date, interaction between the sympathetic nervous
system and pro-inflammatory cytokine signaling
remains poorly understood, despite the fact that both
play an important role in the development of heart
failure.
Recent studies have demonstrated that Epac regulates
cytokine signaling in macrophages and endothelial cells
[22–24]. We thus hypothesized that a novel cAMP/Epac
signaling mechanism regulates cardiac function in heart
failure, working independently of the PKA-mediated
enforcement of cardiac contractility. In the study reported
here, we show that activation of the cAMP/Epac pathway
protects the cardiac myocytes against cytokine-induced
dysfunction, most likely through inhibition of the Jak-
STAT pathway via SOCS3, with subsequent changes in
iNOS expression. These results suggest that Epac plays a
key role in pro-inflammatory cytokine-induced cardiac
dysfunction.
Materials and methods
Reagents
All chemicals were purchased from Sigma (St. Louis, MO),
except for 8-(4-chlorophenylthio)-20-O-Me-cAMP-AM (8-
CPT-AM), which was purchased from Biolog Life Science
Institute (Bremen, Germany).
Myocyte preparation
Primary cultures of neonatal rat cardiac myocytes and adult
rat ventricular myocytes were prepared as described in our
previous publications [24, 25].
Immunoblotting
Immunoblotting was conducted using commercially avail-
able antibodies. Signal transducer and activator of tran-
scription 1 (STAT1), STAT3, phosphor-STAT1 (Tyr701)
and phosphor-STAT3 (Tyr705) antibodies were purchased
from Cell Signaling Technology (Danvers, MA). iNOS and
SOCS3 antibodies were purchased from Immuno-Biologi-
cal Laboratories Inc. (Minneapolis, MN) and Cayman
Chemical (Ann Arbor, MI), respectively. Protein expres-
sion was quantified by densitometry.
Real-time quantitative PCR
Total RNA was extracted using TRIzol Reagent (Invitro-
gen, Thermo Fisher Scientific, Carlsbad, CA ) according to
the manufacturer’s protocol. Total RNA was reverse-tran-
scribed with the SuperScript First-Strand Synthesis System
for RT-PCR kit (Invitrogen) according to the manufac-
turer’s instructions.
mRNA expression of SOCS3 and SOCS1 was quantified
by quantitative real-time PCR using the ABI-PRISM 7700
sequence detection system (Applied Biosystems, Thermo
Fisher Scientific, Foster City, CA)with the SYBRGreen PCR
Master Mix. The primer pairs for SOCS3 and SOC1 were:
SOCS3 (forward, 50-CTGGACCCATTCGGGAGTTC-30;
reverse, 50-AACTGGGAGCTACCGACCATTG-30) and
SOCS1 (forward, 50-CTGCGGCTTCTATTGGGGAC-30;
reverse, 50-AAAAGGCAGTCGAAGGTCTCG-30). The rel-
ative amount of mRNA of SOCS3 and SOCS1 was normal-
ized to 18S rRNA.
Measurements of intracellular Ca21 concentration
and myocyte shortening
Freshly isolated adult rat myocytes were placed on a
laminin-coated 3-cm dish and incubated with or without
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8-CPT-AM (10 lmol/L) for 5 h in medium at 37 C before
dye loading or measurement of myocyte shortening.
Myocytes were loaded together with the fluorescent
indicator fura-2 acetoxymethyl ester (fura-2 AM; Molec-
ular Probes, Thermo Fisher Scientific, Eugene, OR) as
described previously, with some modifications [26]. In
brief, 5 lL of a 1 mmol/M stock solution of fura-2 AM
(dissolved in dimethyl sulfoxide) was added to cells in
2.0 ml Tyrode solution (in mM: HEPES, 5; NaCl, 140;
KCl, 5; MgCl2, 1; glucose, 10; CaCl2, 1.8; pH adjusted to
7.4 with NaOH) to give a final fura-2 concentration of
5 lmol/L. Cells were loaded for 20 min at room temper-
ature, then washed in Tyrode solution twice to remove
unincorporated fura-2 AM and incubated with or without
the addition of IL-6 (30 ng/ml) for 30 min at room tem-
perature before the response of intracellular Ca2? to iso-
proterenol (ISO) was measured.
Conversion of fura-2 fluorescence ratio to intracellular
Ca2? concentration was performed as described previously,
with some modifications [27, 28]. In brief, the fura-2-loa-
ded cells were placed on the stage of an inverted micro-
scope (Nikon Eclipse TE2000; Nikon Corp., Tokyo,
Japan). To measure intracellular Ca2? concentration, we
alternatively illuminated myocytes with 340- and 380-nm
light using a high-speed wavelength-switching device
(Lambda SC; Shutter Instruments Co., Novato, CA), and
images were recorded with an electron-multiplying charge-
coupled device camera (Evolve 512; Photometrics, Tucson,
AZ). The images were analyzed using image analysis
software (NIS-Elements 3.1; Nikon Corp.). Regions of
interest (ROIs) were selected in isolated adult rat myocytes,
and fluorescence signals were monitored in the created
ROIs in the presence or absence of 8-CPT-AM (10 lmol/
L) for 30 s at baseline [29]. The ISO-induced elevation of
the fluorescence signal was then monitored at increasing
Ca2? concentrations (10-7, 10-6 and 10-5 M) in the
presence of ISO for 30 s. Mean fluorescence signals were
converted to free Ca2? concentration by accessing NIS-
Element ratio dialogs.
Measurements of myocyte shortening in response to ISO
were performed as described previously with or without the
addition of IL-6 (30 ng/ml) for 30 min at room temperature
before the measurements [30].
Statistical analysis
All data were presented as mean ± standard error of the
mean. Data were compared using Student’s t test when two
samples were considered or using analysis of variance
followed by Bonferroni posttest for three or more samples.
Differences were considered to be significant at p\ 0.05.
Results
Effects of various cytokines on the Jak-STAT
pathway in cardiac myocytes
Lipopolysaccharide injection is known to increase the serum
levels of cytokines, such as IL-1b, IL-6, IL-10, IL-17,
interferon gamma (IFN-c), KC (keratinocyte-derived che-
mokine), MCP-1 (monocyte chemotactic protein-1),
RANTES (regulated upon activation, normal T cell expres-
sed and secreted) and TNF-a, and thereby augments tyrosine
phosphorylation of STAT3 in the liver and kidneys [31, 32].
However, the contribution of these cytokines to STAT
phosphorylation in the heart has not been well studied. We
first examined to what extent each cytokine contributed to
the phosphorylation of STAT in neonatal rat cardiac myo-
cytes. Phyosphorylation of STAT3 at Tyrosine 705 (Tyr705)
was significantly and strikingly increased in response to IL-6
(14-fold) (Fig. 1a), but not to other cytokines, with phos-
phorylation peaking at 30 min after treatment with IL-6
(Fig. 1c). Phosphorylation of STAT1 at Tyrosine 701
(Tyr701) was significantly increased in response to IL-6 (2-
fold) and IFN-c (13-fold), but not to other cytokines
(Fig. 1b), and IL-6-mediated phosphorylation of STAT1
also peaked at 30 min (Fig. 1d). Thus, among the various
cytokines examined, our results show that IL-6 may play an
important role in the activation of the Jak-STAT pathway, a
major cytokine signaling pathway, in the heart.
Effects of Epac on activation of the Jak-STAT
pathway in response to IL-6
Epac1 has recently been shown to modulate cytokine sig-
naling in non-cardiac cells, such as macrophages or
endothelial cells, in vitro [22, 23, 33]. We thus examined
the consequences of Epac activation on IL-6 signaling, as
shown above, on cardiac myocytes. IL-6-stimulated phos-
phorylation of STAT3 and STAT1 was examined after
treatment of the cells with 8-CPT-AM, an Epac-selective
cAMP analog [34]. While 8-CPT-AM (10 lmol/L) had no
effect on basal phosphorylation of STAT3 or STAT1 in
neonatal rat cardiac myocytes, pretreatment with 8-CPT-
AM for 5 h significantly diminished the IL-6-induced
phosphorylation of STAT3 (Fig. 2a) and STAT1 (Fig. 2b).
Thus, pharmacological activation of Epac did not alter
basal phosphorylation, but it did potently inhibit IL-6-in-
duced STAT phosphorylation. On the other hand, in the
presence of Epac1 selective inhibitor CE3F4 (10 lmol/L),
IL-6-induced STAT3 phosphorylation was significantly
enhanced (Fig. 2c), suggesting that endogenous Epac1
inhibits IL-6-induced STAT3 phosphorylation.
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Epac activation increased SOCS3 and SOCS1 levels
Among the negative regulators of the Jak-STAT pathway,
we found that the mRNA expression of SOCS3 and SOCS1
was increased by Epac activation (Fig. 3). SOCS3 mRNA
expression was significantly increased at 1 h after 8-CPT-
AM treatment (10 lmol/L) by 1.7-fold (p\ 0.05, n = 4)
(Fig. 3a), and SOCS1 mRNA expression was significantly
increased at 3 h after 8-CPT-AM treatment (Fig. 3b) by
6.2-fold (p\ 0.01, n = 3–4). These data suggest that Epac
activation induces mRNA expression of SOCS3 and
SOCS1 and that these molecules may function as negative
Fig. 1 Effects of various cytokines on signal transducer and activator
of transcription (STAT) phosphorylation and the time course of
interleukin (IL)-6-mediated STAT phosphorylation. a Phosphorylation
of signal transducer and activator of transcription 3 (STAT3) at
Tyrosine 705 (Tyr705) was examined at 30 min after treatment with
IL-6 (30 ng/ml), IL-1b (10 ng/ml), IL-10 (10 ng/ml), IL-17 (10 ng/
ml), interferon gamma (IFN-c; 10 ng/ml), keratinocyte-derived
chemokine (KC; 50 ng/ml), monocyte chemotactic protein-1 (MCP-
1; 10 ng/ml), RANTES (regulated upon activation, normal T cell
expressed and secreted; 10 ng/ml), and tumor necrosis factor alpha
(TNF-a; 10 ng/ml). The phosphorylation was upregulated by 14-fold
in response to IL-6 (n = 4, *significantly different at p\ 0.05,
Student’s t test). T-STAT Total STAT, P-STAT phosphorylated STAT.
b Phosphorylation of signal transducer and activator of transcription 1
(STAT1) at Tyrosine 701 (Tyr701) was examined at 30 min after
treatment with IL-6 (30 ng/ml), IL-1b (10 ng/ml), IL-10 (10 ng/ml),
IL-17 (10 ng/ml), IFN-c (10 ng/ml), KC (50 ng/ml), MCP-1 (10 ng/
ml), RANTES (10 ng/ml) and TNF-a (10 ng/ml). The phosphoryla-
tion was upregulated by 13-fold in response to IFN-c and by 2-fold in
response to IL-6 (n = 4, *significantly different at p\ 0.05,
Student’s t test). c Time course of IL-6 (30 ng/ml)-mediated STAT3
phosphorylation at Tyr705. Phosphorylation peaked at 30 min after
treatment with IL-6 (30 ng/ml) and then decreased gradually [n = 4,
****significantly different at p\ 0.0001 vs. 0 h, one-way analysis of
variance (ANOVA)]. d Time course of IL-6 (30 ng/ml)-mediated
phosphorylation of STAT1 at Tyr701. Phosphorylation peaked at
30 min after treatment with IL-6 and then decreased gradually
(n = 4–6, ****significantly different at p\ 0.0001 vs. 0 h, one-way
ANOVA). Data are presented as the mean ± standard error of the
mean (SEM)
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regulators of the IL-6-mediated Jak-STAT pathway acti-
vation in the 8-CPT-AM-treated cardiac myocytes.
Epac-mediated SOCS3 expression via phospholipase
C/protein kinase C
We next examined the role of phospholipase C (PLC) and
protein kinase C (PKC) in the increase of SOCS3 due to
8-CPT-AM treatment because a recent study indicates that
those proteins are involved in cAMP elevation-induced
SOCS3 accumulation in COS cells [35]. As expected, these
increases were abolished in the presence of the PLC inhibitor
U73122 (Fig. 4a) or PKC inhibitor Ro-31-7549 (Fig. 4b),
suggesting that Epac activation increased SOCS3 expression
via PLC/PKCmediation. Taken together, these results led us
to hypothesize that Epac increases SOCS3- and inhibits IL-
6-mediated phosphorylation of STAT in cardiac myocytes.
Effects of Epac activation on IL-6-induced iNOS
expression in cardiac myocytes
To address the functional consequence of Epac-mediated
regulation of IL-6 signaling, we examined changes in
molecules whose expression may be directly regulated by
Fig. 2 Effects of exchange protein activated by cAMP (Epac) on the
activation of the Janus kinase–signal transducers and activators of
transcription (Jak-STAT) pathway in response to IL-6. a, b Pretreat-
ment of neonatal rat cardiac myocytes with 8-(4-chlorophenylthio)-20-
O-Me-cAMP-AM (8-CPT-AM; 10 lmol/L) for 5 h significantly
reduced both IL-6-mediated phosphorylation of STAT3 at Tyr705
by 57 ± 11.5% (a) (n = 5–6, **significantly different at p\ 0.01,
Student’s t test) and IL-6-mediated phosphorylation of STAT1 at
Tyr701 by 65 ± 6.8% (b) (n = 6–8, ****significantly different at
p\ 0.0001, Student’s t test). c Pretreatment of neonatal rat cardiac
myocytes with Epac1 selective inhibitor CE3F4 for 30 min signifi-
cantly enhanced IL-6-mediated phosphorylation of STAT3 at Tyr705
by 35 ± 13.0% (n = 6, *significantly different at p\ 0.05, one-way
ANOVA). Data are presented as the mean ± SEM
J Physiol Sci
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IL-6/Jak/STAT and which also play an important role in
regulating cardiac function. We found that iNOS protein
expression was increased by IL-6 (30 ng/ml) in a time-
dependent manner, with a maximal increase of 4.5-fold at
6 h after IL-6 treatment (Fig. 4c), but that this increase was
significantly inhibited by a 5-h pretreatment with 8-CPT-
AM (10 lmol/L). These results led us to conclude that
pharmacological activation of Epac inhibited the expres-
sion of iNOS.
Effects of Epac on Ca21 regulation and cell
shortening in cardiac myocytes
Cardiac contraction and relaxation are influenced by the
intracellular increase in Ca2? during systole and its
decrease during diastole. Ca2? uptake by the sarcoplasmic
reticulum is regulated via phospholamban phosphorylation
and its release is regulated via the ryanodine receptor. We
previously demonstrated that the basal and peak intracel-
lular Ca2? concentration is significantly decreased in iso-
lated cardiac myocytes of Epac1-null mice compared with
wild-type controls, with reduced phospholamban phos-
phorylation at the serine 16 residue [7]. In that same study,
we also demonstrated that silencing Epac1 in cardiac
myocytes attenuated ISO-mediated increases in phospho-
rylation of the ryanodine receptor on the serine 2808 and
serine 2814 residues [7]. These data suggest that Epac1
activation, on its own, can cause changes in Ca2? signaling
and contractility in isolated cardiac myocytes.
IL-6 has been shown to decrease the intracellular Ca2?
concentration and cell contraction in cultured chick cardiac
myocytes through the induction of iNOS [36]. Our findings
suggest that Epac can increase SOCS3 and SOCS1
expression, leading to inhibition of STAT3 phosphoryla-
tion and, consequently, iNOS expression. Consequently, it
is possible that Epac antagonizes IL-6 with respect to
regulation of the Ca2? concentration and thus cell con-
traction. In our study, ISO increased the intracellular Ca2?
concentration in a dose-dependent manner in adult rat
cardiac myocytes. This increase was significantly attenu-
ated when the cells were pretreated with IL-6 (30 ng/ml)
for 6 h, as expected (Fig. 5a). However, pretreatment with
8-CPT-AM (10 lmol/L) for 5 h abolished this attenuation
by IL-6 (Fig. 5b). When myocyte shortening was examined
as an index of cardiac contractility, ISO (10-5 mol/L)
significantly increased cell shortening, and this increase
was significantly attenuated by IL-6 (30 ng/ml) pretreat-
ment for 6 h (Fig. 5c). Importantly, pretreatment with
8-CPT-AM for 5 h abolished this attenuation with IL-6
(Fig. 5d). Taken together, these findings suggest that
pharmacological activation of Epac plays a key role in
antagonizing IL-6, resulting in preservation of the Ca2?
regulation and thus preservation of cardiac contractility, at
least in cultured myocytes.
Discussion
Interleukin-6 inhibited the increase in intracellular Ca2?
concentration and thereby also myocyte shortening stimu-
lated by ISO. This effect of IL-6 was diminished by
pharmacological activation of Epac in cardiac myocytes,
Fig. 3 Time course of Epac-mediated expression of suppressor of
cytokine signaling-3 and -1 (SOCS3, SOCS1, respectively) in cardiac
myocytes. a, b mRNA expression of SOCS3 (a) and SOCS1 (b) was
examined by quantitative real-time PCR in neonatal rat cardiac
myocytes in the presence of 8-CPT-AM (10 lmol/L) for the indicated
time. mRNA expression of SOCS3 and SOCS1 gradually increased
with 8-CPT-AM treatment. a SOCS3 mRNA expression peaked at a
significant increase of 1.7-fold at 1 h after 8-CPT-AM treatment
(n = 4, *significantly different at p\ 0.05 vs. baseline, one-way
ANOVA). b SOCS1 mRNA expression peaked at a significant
increase of 6.2-fold at 3 h after 8-CPT-AM treatment (n = 3–4,
**significantly different at p\ 0.01 vs. baseline, one-way ANOVA).
NS Not significant. Data are presented as the mean ± SEM
J Physiol Sci
123
most likely through SOCS3/STAT/iNOS signaling. It has
long been believed that the major target of catecholamine/
cAMP signaling is PKA and that the PKA-mediated
increase in myocyte contractility is the only mechanism
compensating for cardiac dysfunction in heart failure.
However, our findings suggest that there is another
Fig. 4 Effects of Epac activation on SOCS3 expression and IL-6
induced inducible nitric oxide synthase (iNOS) expression in cardiac
myocytes. a SOCS3 mRNA expression, examined by quantitative
real-time PCR in neonatal rat cardiac myocytes in the presence of
8-CPT-AM (10 lmol/L) for 1 h, was significantly increased by 1.8-
fold. However, Epac-mediated SOCS3 upregulation was blunted by
the addition of a phospholipase C (PLC) inhibitor (U73122, 0.5 lmol/
L) or protein kinase C (PKC) inhibitor (Ro-31-7549, 2 lmol/L)
(n = 6–10, ***significantly different at p\ 0.001 vs. baseline, one-
way ANOVA). b SOCS3 protein expression, examined by western
blotting in the presence of 8-CPT-AM (10 lmol/L) for 5 h, was
significantly increased by 2.2-fold in the presence of 8-CPT-AM. This
upregulation was also blunted by the addition of PLC inhibitor or
PKC inhibitor (n = 6–11, ****significantly different at p\ 0.0001
vs. baseline, one-way ANOVA). c Western blot analysis of iNOS
expression in neonatal rat cardiac myocytes treated for the indicated
times with IL-6 (30 ng/ml). iNOS expression increased gradually,
peaking at 6 h. However, pretreatment with 8-CPT-AM (10 lmol/L)
for 5 h inhibited the IL-6-mediated increase of iNOS protein
expression (n = 4–7, *significantly different at p\ 0.05, two-way
ANOVA). GAPDH Glyceraldehyde 3-phosphate dehydrogenase.
Data are presented as the mean ± SEM
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mechanism that involves Epac and that this mechanism
may be able to restore cardiac myocyte function, at least in
the context of cytokine-induced dysfunction. Thus, Epac
appears to play an important role, unlike PKA, in the
crosstalk between the sympathetic nervous system and pro-
inflammatory cytokine signaling in the development of
heart failure.
Of the various cytokines examined in our study, we
found that IL-6 was the most prominent activator of
STAT3 in cardiac myocytes and that IL-6-mediated
STAT3 activation reduced the ISO-induced increase in
Ca2? concentration and cardiac contractility through the
induction of iNOS. We also demonstrated that IL-6 sig-
nificantly increased the phosphorylation of STAT1 even
though IFN-c is the most prominent activator of STAT1 in
cardiac myocytes. Also, IL-6-mediated STAT1 activation
was significantly decreased by the activation of Epac in
cardiac myocytes. Previous studies have shown that
STAT1 phosphorylation may be able to induce iNOS
expression with the activation of p44/42 mitogen-activated
protein kinase in cardiac myocytes [37]. Taken together,
these results suggest that cytokine-mediated cardiac dys-
function is most likely mediated by nitric oxide production
[14, 38]. We also found that this deterioration can be
ameliorated by Epac activation. Cytokine levels are
increased in patients with chronic congestive heart failure
[14], in whom sympathetic nerve activity is also increased,
suggesting that Epac activation may be beneficial in such
patients, in addition to those with septic heart failure.
Our observation of an increase in SOCS3 mRNA/protein
levels in cardiac myocytes in response to Epac activation is
consistent with previous findings. For example, elevated
cAMP levels have been found to promote SOCS3 accu-
mulation in cultured cell lines, such as mouse embryonic
fibroblasts or COS cells [22, 35, 39], most likely through
the PLC/PKC pathway, as demonstrated in COS cells [35].
We also confirmed the increase in SOCS1 mRNA level in
cardiac myocytes in response to Epac activation, which is
known to exert negative feedback effects on cytokine sig-
naling via the Jak-STAT pathway [40, 41]. More
Fig. 5 Effects of Epac activation on Ca2? concentration (a, b) and
contractility of cardiac myocytes (c, d). a Intracellular Ca2?
concentration in response to increasing concentrations of isopro-
terenol (ISO; 0–10-5 mol/L) in adult rat cardiac myocytes with or
without a 6-h IL-6 (30 ng/ml) pretreatment. b The effect of a 5-h
8-CPT-AM (10 lmol/L) pretreatment on the ISO-induced increase of
Ca2?. Pretreatment with 8-CPT-AM restored the increase of Ca2?
transients suppressed by IL-6 (n = 29–64, **significantly different at
p\ 0.01, two-way ANOVA). c Cardiac cell shortening at baseline
and in response to ISO (10-5 mol/L). d Pretreatment with 8-CPT-AM
(10 lM) restored cell shortening suppressed by IL-6 (30 ng/ml)
(n = 24–31, ****significantly different at p\ 0.0001, two-way
ANOVA). Data are presented as the mean ± SEM
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importantly, SOCS1-deficient mice are sensitive to LPS-
induced lethal effects than wild-type control mice [42]. In
our study, however, we demonstrated the functional sig-
nificance of such changes, i.e., that Epac increased mRNA
expression of SOCS3 and SOCS1 in cultured cardiac
myocytes, thereby inhibiting IL-6/STAT/iNOS signaling
and protecting the cardiac myocytes against cytokine-in-
duced dysfunction.
Our findings suggest that the beneficial effect of the
sympathetic nervous system involves not only enhance-
ment of cardiac contractility through the classic cAMP/
PKA pathway, but also inhibition of the Jak/STAT path-
way via the newly described cAMP/Epac pathway. Epac
signaling can attenuate pro-inflammatory cytokine-induced
Jak/STAT signaling via SOCS3 and SOCS1, leading to the
downregulation of iNOS, which is associated with cardiac
dysfunction. It is known that cardiac dysfunction in sepsis
is severe but that it may be restored almost completely in
many cases [18, 19]. In cardiac myocytes, IL-6 treatment
increases phosphorylation of STAT3 at the Tyr705 through
the enhanced de novo synthesis of iNOS protein, leading to
increased NO production and decreased cardiac contrac-
tility [38]. Furthermore, both IL-6-mediated STAT3
phosphorylation at Tyr705 and iNOS expression are
blocked by AG490, a Jak2 inhibitor, or by genistein, a
protein tyrosine kinase inhibitor, in cardiac myocytes [38].
IL-6 treatment also inhibits the ISO-induced increase in
Ca2? level and decreases cell contraction in cardiac myo-
cytes [36]. However, pretreatment with NG-monomethyl-L-
arginine, an analog of L-arginine and a potent inhibitor of
NO production, inhibits the IL-6-mediated decrease in
intracellular Ca2? transient and cell contraction in cardiac
myocytes [36]. These previous data, together with the data
from our study, indicate the causal relationship and func-
tional significance of such changes, i.e., that Epac
increased the expression of SOCS3 and SOCS1 in our
cultured cardiac myocytes, thereby inhibiting IL-6/STAT/
iNOS signaling and protecting the cardiac myocytes
against cytokine-induced dysfunction.
Epac activation has been reported to increase myofila-
ment Ca2? sensitivity of isometric force through the
increased phosphorylation of two key sarcomeric proteins,
namely, cardiac myosin binding protein-C and cardiac
troponin I [43], and it might also contribute to the Epac-
mediated compensation of cardiac dysfunction in sepsis.
We speculate that cAMP/Epac-mediated cardiac protec-
tion, as opposed to the cardiac damage caused by cytoki-
nes/endotoxin, may explain this beneficial effect, at least in
part. Thus, we consider that the sympathetic nervous sys-
tem can regulate cardiac function through multiple
mechanisms.
In summary, we have demonstrated that Epac-mediated
SOCS3 and SOCS1 expression protects the heart against
cytokine-mediated cardiac dysfunction by inhibiting
STAT3 phosphorylation and subsequent iNOS production.
Our findings also suggest that Epac1 and its downstream
pathway, including Jak2 or STAT3, may be an attractive
target for treatment of cardiac failure in sepsis, and pos-
sibly cardiac failure in general, since cytokine-induced
cardiac dysfunction plays an important role in the patho-
genesis of cardiac failure [21].
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